Janssen Biotech discontinued development of prizloncabtagene autoleucel (C-CAR039), an anti-CD20/CD19 bispecific CAR T therapy, and Abelzeta Pharma regained all rights outside China. The decision follows a 2023 licensing agreement under which Abelzeta originally out-licensed global rights excluding China to Janssen. For Abelzeta, regaining rights offers a path to refocus development strategy and potentially reallocate resources within its cell therapy pipeline. Janssen’s exit also signals how portfolio priorities and trial expectations can reshape CAR T ownership and timelines. This type of rights reversal remains a key mechanism for capital efficiency in cell therapy—assets can move quickly when larger partners reassess risk/benefit.